Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perillyl Alcohol in Resectable Pancreatic Cancer
NCT00003769Phase 2Completed
- Sponsor
- Indiana University School of Medicine
- Start
- Feb 1999
- Primary completion
- Jul 2001
- Modality
- Nucleic Acid-Directed Small Molecules, Inhalation Devices, Covalent Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NEO100-02 in pancreatic cancer (PC), sponsored by Indiana University School of Medicine. Primary endpoints: Biologic activity at 14 days, Acute toxicity at 14 days and 2 more. Started Feb 1999; status: completed.
02
Drugs
NEO100-02
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00003769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003769.